objective. To determine the cost of management of occupational exposures to blood and body fluids.
Occupational exposures to blood through needle sticks and other injuries from sharp objects, contact with mucous membranes, and splashes to nonintact skin are frequently reported by healthcare personnel. 1, 2 The Centers for Disease Control and Prevention (CDC) has estimated that approximately 1,000 injuries from sharp objects are sustained daily in US hospitals. 2 Up to 50% of some types of surgery result in a mucocutaneous contact with blood, [3] [4] [5] [6] [7] and at least half of these exposures in operating rooms are from blood-hand contacts. 4, 6 Exposures such as these have the potential for transmission of bloodborne viruses such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). 1, 8, 9 The risk of infection transmission is greatest through percutaneous exposures to blood, that is, from needle sticks or cuts or punctures from sharp objects. [4] [5] [6] Although needle sticks and other injuries from sharp objects have been associated with the transmission of up to 30 different pathogens, 10 the 3 pathogens of greatest concern for healthcare personnel-HBV, HCV, and HIV-are all bloodborne. 1, 8, 9 Transmission rates for HBV, 8 HCV, 1, [11] [12] [13] and HIV 9 vary by pathogen but are estimated to be 6%-30% for HBV and 0.3% for HIV after a percutaneous exposure. HCV transmission rates have been reported to be between 0.5% and 10%, with an average of approximately 1.8%. 1, [11] [12] [13] In addition, transmission rates vary by type and severity of exposure; for example, the HIV transmission rate is estimated to be 0.3% for a percutaneous exposure, 0.1% for a mucous membrane exposure, and even lower for a nonintact skin exposure. 9 Although seroconversion is an infrequent event, healthcare employers have a responsibility to their personnel to prevent 14 Comprehensive guidelines for management of occupational exposures to HBV, HCV, and HIV were published in 2001, 15 and updates to the management guidelines for HIV exposure were published in 2005 . 16 The 2001 guidelines give practice recommendations for the management of occupational exposures to bloodborne pathogens and advise an administration-level approach for establishing an exposure-management protocol in a healthcare institution. 15 The flow of resources used to implement the management practices recommended by the guidelines is illustrated in Figure 1 . The processes involved in exposure management include (1) exposure reporting and assessment of infection risk, including assessment of the type and severity of exposure and bloodborne infection status of the source patient; (2) initial wound management and postexposure prophylaxis (PEP); and (3) follow-up and counseling for the exposed personnel. 15 Appropriate management of occupational exposures can require expenditures by healthcare institutions. Furthermore, exposure management, including testing, treatment, and counseling, can have physical and emotional side effects for the exposed healthcare personnel. 17, 18 In assessing the costs borne by a healthcare institution, one can consider both dollars and time expended not only by the exposed employee but also by all staff involved in the management of an exposure. An injured healthcare personnel exposed to a bloodborne virus should have initial testing, counseling, and follow-up. This may require labor by occupational healthcare personnel (eg, physicians, nurses, pharmacists, laboratory workers, and phlebotomists); likewise, the source patient must be counseled and tested, which requires additional labor, testing, and supplies.
Previous studies have addressed the costs involved in exposure management. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] A review of these studies found that the estimated average cost per exposure (to the healthcare institution) ranged from $51 to $3,766 (in 2002 US dollars) and that the variability in costs was a result of differences in study methodology and/or the protocols for exposure management in the study institutions. 36 Limitations of these studies include reliance on information from only a single facility, use of multiple assumptions about salaries, and limited information on both the type of pathogen to which the healthcare personnel were exposed as well as exposure severity. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Also, many of these studies are more than 10 years old. We therefore assessed recent costs of management of occupational exposures to blood and body fluids and the effect of factors such as exposure type, healthcare worker type, and exposure severity on costs to the hospital. This cost analysis was done from the perspective of hospital administrators (ie, excluding costs resulting from possible disease transmission and the societal costs resulting from any morbidity and mortality attributable to the exposure), because they are usually ultimately responsible for making the decisions regarding commitment of resources to exposure management. These data are important for evaluation of the benefits (cost savings) of interventions to prevent occupational exposures (eg, the adoption of needle devices with engineered safety features) and can be combined with data on the incidence of injury to estimate the cost to the healthcare institution. 37, 38 methods Data were collected in 2003 from a convenience sample of 4 different facilities: a 600-bed public hospital, a 244-bed Veterans Affairs medical center, a 437-bed rural tertiary care hospital, and a 3,500-bed healthcare system. Facilities with varying organizational characteristics were chosen to capture the costs across different organizations. A standardized datacollection form was used to collect information about a variety of exposures that differed in type and severity. Severity was classified on the basis of exposure type, volume of exposure (small or large), and the infection status of the source patient, which is consistent with CDC/USPHS guidelines. 15, 16 Detailed information on actual costs (eg, of tests and supplies), time spent, and salary for all involved, including both the exposed personnel and the staff who managed the exposure, was collected. Each facility was asked to provide information for up to 9 hypothetical exposure scenarios (see Table A in the Appendix for a description of scenarios) and to supply actual costs (rather than charges) whenever possible. Facility-specific data supplied to us were based on expert opinion and/or matched our scenarios to actual cases from their records. Lastly, each facility was asked to provide a description of its protocol for exposure management.
Detailed Data Description
The data-collection form was designed to identify all the costs associated with postexposure management that could accrue for the facility, including lost wages for the exposed healthcare personnel from evaluation, testing, and treatment; additional lost wages for the exposed healthcare personnel from work days lost as a result of follow-up appointments and side effects from the treatment; wages of all staff involved in postexposure management (from reporting through follow-up); all laboratory costs for the exposed healthcare personnel and the source patients; and all drug costs associated with PEP for HBV and HIV exposures. For each of these categories-cost, time expended, and wages-the following data were provided: range (minimummaximum), probability of extremes, most frequent response, and probability of most frequent response. Personnel salaries were based on real wage figures at each of the facilities, and a weighted average from the frequencies of the actual wages was calculated for use in our cost computation. Time costs were subdivided into time costs for the exposed employee and time costs for all other staff involved in the exposure management. Time cost for the exposed employee included time for initial reporting and treatment, time spent for followup appointments, and additional work time missed due to side effects of PEP. Time cost for staff involved in the exposure management process included time for initial reporting, initial source testing, source patient testing and counseling, and follow-up appointments and counseling for the exposed employee. Total cost components were computed as wages (including benefits) lost to PEP adverse events, costs of source tests, laboratory costs, costs of PEP, personnel wages, and wages of the exposed healthcare personnel. Data on costs for management of seroconversion for healthcare personnel, workers' compensation fees, and other peripheral costs were not collected. The mean total cost may vary slightly from the sum of the cost components because the mean total cost often included negligible costs of supplies and the cost of medications for the side effects of HIV postexposure prophylaxis (eg, antimotility medications).
Costs Versus Charges and Unit Cost
Costs were assessed from an institutional perspective and thus were considered in terms of actual costs rather than charges. Further, costs were "unit costs," which included in each unit a fixed, proportioned-per-service cost for overhead-for example, room allocation or facility maintenance. This was done to ensure consistency across the 4 facilities. The time frame of the analysis (the length of time associated with a treatment or an intervention) corresponds to the length of time in which hospital personnel and resources are used for postexposure management. Consistent with the hospital-level perspective of this cost analysis, the analytic horizon of the analysis (the time period during which the costs of postexposure management accrue) considers only these hospital costs and does not consider the potential costs associated with seroconversion. Although the costs saved by prevention of disease (especially HIV) can be substantial, these benefits are more diffuse and can accrue to parties other than the hospital. Because this study is a cost analysis of postexposure management (as opposed to a cost-effectiveness analysis), these cost savings were not measured. 39 
results
We analyzed data for 31 reported exposure scenarios: 5 (16%) mucosal exposures, 9 (29%) cutaneous exposures (2 involving intact skin and 7 involving nonintact skin), and 17 (55%) percutaneous exposures. The characteristics of these exposures are summarized in Table 1 . The exposure management protocols for each of the 4 facilities were consistent with USPHS guidelines. 15 The infection status for the source patients in 31 exposure scenarios was as follows: 19 were HIV positive, 8 were HBV positive, 14 were HCV positive, 6 had unknown status, and 2 were not infected (Tables 1 and 2 ). Some of the source patients were coinfected with HIV and HBV and/or HCV (hereafter, "HIV coinfected"). Infection status was classified as unknown or not infected, HCV positive only, HIV positive only, and HIV coinfected (8, 4, 7 , and 12 patients, respectively). There were no source patients infected with only HBV, but 2 were coinfected with HBV and HIV, and 6 were coinfected with HBV, HCV, and HIV. Another 4 were coinfected with HCV and HIV. Eight exposures (29%) were considered to be more severe, and 6 exposures (21%) were large-volume exposures.
Time expended by the exposed healthcare personnel and the staff involved in exposure management represented significant cost in wages lost. Figure 2 shows the mean time expenditure for both the exposed healthcare personnel and the staff involved in exposure management for exposure scenarios involving HIV-coinfected source patients ( ), n p 12 HIV-infected source patients without coinfection ( ), n p 7 and source patients with unknown or negative HIV-infection status (
). Healthcare personnel exposed to HIV-coinn p 8 fected source patients required the greatest amount of personal and professional attention, with a mean total time cost of 452 healthcare personnel minutes (range, 192-740 health- Table 2 .
For all 31 exposures, PEP costs represented 31% of the overall mean cost, whereas laboratory costs (for tests of both the exposed healthcare personnel and the source patients) represented 30%. The wages of the exposed healthcare personnel and the staff comprised the remaining 39% of the overall total cost of management of occupational exposures to blood and body fluids, which had a mean total cost of $1,687 (range, $71-$4,838) per exposure. However, the most appropriate way to reference the most representative mean cost of exposure is to refer to the specific infection status of the source patient.
With regard to the management of the 19 HIV exposures, there were 7 exposures to HIV alone; 2 exposures to HIV and HBV; 4 exposures to HIV and HCV; and 6 exposures to HIV, HBV, and HCV (Table 1) . Healthcare personnel exposed to HIV spent a mean of 459 minutes (range, 192-755 minutes) for reporting exposures and engaging in follow-up for exposures, which represented a mean of $249 (range, $87-$1,051) in wages. Laboratory costs for the exposed healthcare personnel comprised 25% of the overall total cost of management of HIV exposures, whereas laboratory costs for the source patients comprised only 4%. Costs of PEP for HIV and HBV, with a mean of $820 (range, $357-$1,626), comprised the remaining 33% of the overall cost. The overall mean cost for all exposures is shown according to infection status of the source patient in Table 2 . Table 3 presents an accounting of the resource usage across the 3 processes involved in exposure management. The largest proportion of resources were consumed during postexposure follow-up (process 3 in Table 3 ), for which the average cost of follow-up was $848 (50% of total cost). Laboratory costs represented the largest component of follow-up costs, at $422 (50% of follow-up costs). Lost wages for the exposed employee represented the second largest component, at $300 (35% of follow-up costs), but also were the most variable (range, $6-$1,764), depending on the type of worker and the number of hours lost as a result of the exposure. Staff involved in management of exposure follow-up were limited to physicians and nurses. Time spent by staff on the initial evaluation of the exposed healthcare personnel and the source patients represented the largest proportion of the cost of process 1 (44% of mean total cost). The mean cost associated with administration of PEP was $706.
discussion
There have been many previous studies that addressed the cost of management of exposures to blood and body fluids; however, none has measured the costs of all the elements that USPHS recommends be included in exposure management. Table 4 is a modification of a summary table from a systematic review by Lee et al. 36 of the literature on the epidemiologic and economic impact of needlestick injuries in US hospitals. We expanded the table to include additional studies and the cost perspective of each study. Our study considers all possible costs of management of exposures to blood and body fluids borne by a healthcare facility, excluding the cost of management of seroconversion and the psychological toll on those involved in exposure management. Many of the other studies did not provide or describe the individual cost components, and it was difficult to determine what comprised their final cost estimate. Further, some studies did not include testing of the source patient, considered only the PEP costs for 1 type of infection, or had a cost perspective that included a broader social perspective (such as calculation of disabilityadjusted life years). We deliberately collected cost estimates from different types of healthcare facilities and for a variety of scenarios, to get a more complete picture of the range of costs of exposure management for a hospital. To aggregate costs among the facilities, we captured unit costs instead of charges from each facility. Further, we have described the allocation of resources and costs across the work processes that comprise exposure management, providing a picture of where costs accrue as the various tasks are performed. This gives a more complete picture of the real costs of management of exposures to blood and body fluids at the hospital level. It is important to note, however, that our data are not necessarily generalizable to all healthcare facilities. Our data overall represent the more extreme end of the exposure spectrum, because 19 (61%) of 31 observations involved HIV exposure and only 8 (25%) involved source patients who were uninfected or had unknown infection status. In the CDC's occupational exposure surveillance system (NaSH), only approximately 5% of reported exposures to blood and body fluids involved source patients infected with HIV, and approximately 12% involved any bloodborne pathogen (A.L.P., unpublished CDC data). Moreover, 12 of our observations involved source patients positive for more than 1 pathogen, which further inflates the mean total cost. So, our mean total costs may be overestimates because of the overrepresentation of exposures to infected source patients. Thus, we caution against looking at the total mean costs; instead, one should look at our report of the total costs stratified by pathogen and by process components of the management protocol.
Nonetheless, management of exposures to uninfected source patients or exposures in which the source is unknown still accrues an average cost of $376 (range, $71-$860; 8 exposures), thus, these exposures still require expenditure by hospitals, albeit less than for exposures to infected source patients. Further, as shown in Table 3 , the mean cost of process 1 ($296) is lower than the mean costs of the other 2 processes ($563 for process 2 and $848 for process 3). Because most exposures managed by facilities are likely to be exposures to uninfected source patients, the costs from processes 2 and 3 would contribute little to the total costs of exposure management for a large number of exposures. The primary economic impact of occupational exposures to blood and body fluids is from the costs of HIV PEP, the costs of all laboratory tests, and all time lost by the exposed healthcare personnel and the staff involved in exposure management. More than 50% of the final mean cost came from HIV PEP, laboratory tests, and follow-up appointments, which shows that it is more expensive to manage exposures to HIV-positive source patients than exposures to HIV-negative source patients. These cost data could be used to perform a cost-effectiveness analysis of adopting measures for prevention of exposures, including the use of safety devices or the provision of safety training for sharp instruments.
The guidelines for exposure management do not provide much leeway for economizing; that is, it is difficult to shift resources between personnel and materials to reduce costs. Because personnel costs represent a smaller component of the total costs, the avoidance of severe exposures and the costs associated with PEP will achieve a greater reduction of the costs of exposure management. As illustrated in Table 3 , even exposures to uninfected source patients or source patients whose infection status is unknown require expenditures by healthcare facilities, albeit less than for exposures to infected source patients.
Because the data were collected from a small convenience sample of hospitals, the results may not be generalizable to all exposures in all hospitals. It is also difficult to estimate the mean costs for certain situations; in particular, we did not have any cases of exposure to HBV only. Moreover, because our analysis took a narrower cost perspective, we did not collect data on the costs of seroconversion in employees, the costs of recommended worker's compensation insurance, or the emotional or psychological costs to the involved personnel. Lastly, although our data were not randomly selected nor independently made observations, they nevertheless may be worthwhile for assessment of factors that may affect the overall cost of management of occupational exposures to blood and body fluids.
Management of occupational exposures to blood and body fluids is expensive, even if the source patient is not infected. To avoid these costs, healthcare facilities should investigate whether there are cost-effective interventions that can prevent or reduce exposures and help avoid the physical, emotional, and fiscal toll of exposure management. Table A . We assumed that the hospitals' exposure-management protocols did not vary for exposure to HBV and HCV but did vary for exposure to HIV. Hospitals were asked to provide an outline (not policy) of the general elements of exposure management in their facility. Additionally, they were asked about the types of exposure for which they would give 2 or 3 drugs for HIV PEP, their routine for serologic testing for HIV and HCV after exposure, and their routine schedule for monitoring of laboratory abnormalities in healthcare workers receiving PEP. 
